|
|
 |
A platform focused on antibody humanization |
|
|
PX’Monoclonals differentiates from other CROs by its strategy
to evaluate, develop and integrate broad antibody “humanization”
technologies and approaches through collaborations with other
biotech companies or academic laboratories.
The Hu’S-Map programme, approved by the LyonBiopole competitiveness
cluster, will especially address molecular humanization of antibody,
humanized mice generation, and production of human antibody from
immortalized B lymphocytes. These new technologies will be built
up and performed as part of anti-infective therapeutic products
development programme.
|
|
|
 |
